Published in Obesity and Diabetes Week, August 22nd, 2005
For the second quarter of 2005, total operating expenses were $27.6 million, compared with $18.4 million for the second quarter of 2004. Research and development (R&D) expenses increased by $9.3 million to $23.6 million, primarily due to increased costs associated with the company's expanded clinical trials and related support for its Technosphere Insulin program. General and administrative (G&A) expenses decreased by $0.1 million to $4 million.
For the first 6 months of 2005, operating expenses totaled $50.2 million, compared with $35...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.